cDNA microarray profiling of rat cholangiocarcinoma induced by thioacetamide

Molecular Medicine Reports

Volumn 8, Issue 2, 2013, Pages 350-360

  Yeh, Chun Nan ^a   Weng, Wen Hui ^b   Lenka, Govinda ^b   Tsao, Lee Cheng ^b   Chiang, Kun Chun ^a   Pang, See Tong ^a   Chen, Tsung Wen ^a   Jan, Yi Yin ^a   Chen, Miin Fu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

Author keywords

Carcinogenesis; cDNA expression array; Cholangiocarcinoma; Diagnostic markers; Pathway analysis; Thioacetamide

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COMPLEMENTARY DNA; PROTEIN; THIOACETAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERIZATION; PROTEIN EXPRESSION; PROTHROMBIN TIME; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; UNINDEXED SEQUENCE; UPREGULATION;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; MALE; MEMBRANE PROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; RATS; REPRODUCIBILITY OF RESULTS; SYMPORTERS; THIOACETAMIDE;

RATTUS;

EID: 84879982257     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1516     Document Type: Article

References (47)

1. Liver Cancer Study Group of Japan: Classifi cation of Primary Liver Cancer. 1st English edition. Kanehara Press Co., Tokyo, 1997.
2. Yeh CN, Yeh TS, Chen TC, Jan YY and Chen MF: Gross pathological classification of peripheral cholangiocarcinoma determines the efficacy of hepatectomy. J Gastroenterol: Sep 25, 2012 (Epub ahead of print).
3. Chen MF: Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol 14: 1144-1149, 1999.
4. Shaib YH, Davila JA, McGlynn K and El-Serag HB: Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 40: 472-477, 2004.
5. Patel T: Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2: 10, 2002.
6. Chang KY, Chang JY and Yen Y: Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw 7: 423-427, 2009.
7. Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115-125, 2004.
8. DeGroen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med 341: 1368-1378, 1999.
9. Albores-Saavedra J, Henson DE and Sobin LH: The WHO histological classifi cation of tumors of the gallbladder and extrahepatic bile ducts. A commentary on the second edition. Cancer 70: 410-414, 1992.
10. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y and Blumgart LH: Intrahepatic cholangiocarcinoma: resectability, recurrence pattern and outcomes. J Am Coll Surg 193: 384-391, 2001.
11. Uenishi T, Hirohashi K, Kubo S, et al: Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg 25: 865-869, 2001.
12. Jarnagin WR, Fong Y and DeMatteo RP: Staging, resectability and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234: 507-519, 2001.
13. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33: 1353-1357, 2001.
14. Shirabe K, Shimada M and Harimoto N: Intrahepatic cholangiocarcinoma: Its mode of spreading and therapeutic modalities. Surgery 131: S159-S164, 2002.
15. Bathe OF, Pacheco JT and Ossi PB: Management of hilar bile duct carcinoma. Hepatogastroenterology 48: 1289-1294, 2001.
16. Yeh CN, Maitra A, Lee KF, Jan YY and Chen MF: Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 25: 631-636, 2004.
17. Terada T, Nakanuma Y and Sirica AE: Immunohistochemical demostration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 29: 175-180, 1998.
18. Endo K, Yoon BI, Pairojkul C, Demetris AJ and Sirica AE: ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36: 439-450, 2002.
19. Hansel DE, Rahman A, Hidalgo M, et al: Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163: 217-229, 2003.
20. Yeh CN, Pang ST, Wu RC, Chen TW, Jan YY and Chen MF: Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy. Oncol Rep 21: 49-56, 2009.
21. National Institutes of Health: Guide for the Care and Use of Laboratory Animals. NIH publication no. 85-23, revised 1996.
22. Pang ST, Dillner K, Wu X, Pousette A, Norstedt G and Flores-Morales A: Gene expression profi ling of androgen defi ciency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology 143: 4897-906, 2002.
23. Kanehisa M, Goto S, Sato Y, Furumichi M and Tanabe M: KEGG for integration and interpretation of large-scale molecular datasets. Nucleic Acids Res 40: D109-D114, 2012.
24. Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30, 2000.
25. Huang DW, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protoc 4: 44-57, 2009.
26. Huang DW, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13, 2009.
27. Dasgupta A, Chatterjee R and Chowdhury JR: Thioacetamide-induced hepatocarcinoma in rat. Oncology 38: 249-253, 1981.
28. Fitzhugh OG and Nielson AA: Liver tumors in rats fed thiourea or thioacetamide. Science 108: 626-628, 1948.
29. Al-Bader AA, Mathew TC, Abul H, Al-Mosawi M, Panigrahi D and Dashti HM: Bacterial translocation in thioacetamide induced liver cirrhosis. J R Coll Surg Edinb 43: 278-82, 1998.
30. Lee JW, Shin KD, Lee M, et al: Role of metabolism by flavin-containing monooxygenase in thioacetamide-induced immunosuppression. Toxicol Lett 136: 163-172, 2003.
31. Dashti H, Jeppsson B, Hagerstrand I, et al: Early biochemical and histological changes in rats exposed to a single injection of thioacetamide. Pharmacol Toxicol 60: 171-174, 1987.
32. Gallagher CH, Gupta DN, Judah JD and Rees KK: Biochemical changes in acute thioacetamide intoxication. J Path Bact 72: 193-201, 1956.
33. Gupta DN: Acute changes in the liver after administration of thioacetamide. J Pathol Bacteriol 72: 183-192, 1956.
34. Muller D, Zimmerman SI and Schiller F: Drug metabolism in rat liver injured by thioacetamide. Arch Toxicol 5: 368-371, 1982.
35. Dashti HM, Mathew TC, Jadaon MM and Ashkanani E: Zinc and liver cirrhosis: biochemical and histopathologic assessment. Nutrition 13: 206-212, 1997.
36. Sirica AE, Lai GH and Zhang Z: Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol 16: 363-372, 2001.
37. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM and Nebert DW: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14: 1-18, 2004.
38. Henderson CJ, Russell AL, Allan JA and Wolf CR: Sexual differentiation and regulation of cytochrome P-450 CYP2C7. Biochim Biophys Acta 1118: 99-106, 1992.
39. Arun KA and Bernard HS: Latent overexpression of hepatic CYP2C7 in adult male and female rats neonatally exposed to phenobarbital: a developmental profile of gender-dependent P450s. J Pharmacol Exp Ther 293: 1027-1033, 2000.
40. Hagenbuch B, Stieger B, Foguet M, Lübbert H and Meier PJ: Functional expression, cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci USA 88: 10629-10633, 1991.
41. Trauner M, Meier PJ and Boyer JL: Molecular regulation of hepatocellular transport systems in cholestasis. J Hepatol 31: 165-178, 1999.
42. Kjellén L and Lindahl U: Proteoglycans: structures and interactions. Annu Rev Biochem 60: 443-475, 1991.
43. Santra M, Eichstetter I and Iozzo RV: An anti-oncogenic role for decorin. Downregulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem 275: 35153-35161, 2000.
44. Zhang Z, Li XJ, Liu Y, Zhang X, Li YY and Xu WS: Recombinant human decorin inhibits cell proliferation and downregulates TGF-beta1 production in hypertrophic scar fi broblasts. Burns 33: 634-641, 2007.
45. Abhijit GB, Indraneel B, William ML and Jamboor KV: Aberrant expression and localization of decorin in human oral dysplasia and squamous cell carcinoma. Cancer Res 63: 7769-7776, 2003.
46. Pujuguet P, Simian M, Liaw J, Timpl R, Werb Z and Bissell MJ: Nidogen-1 regulates laminin-1-dependent mammary-specific gene expression. J Cell Sci 113: 849-858, 2000.
47. Baxter RM, Crowell TP, George JA, Getman ME and Gardner H: The plant pathogenesis related protein GLIPR-2 is highly expressed in fi brotic kidney and promotes epithelial to mesenchymal transition in vitro. Matrix Biol 1: 20-29, 2007.